Skip to main content

News

All the latest news and information on the main advances in research, institutional milestones, teaching and management. Find out what happens at the Vall d'Hebron Research Institute!

The article on the mortality rate of young people with HIV due to perinatal transmission after transitioning to adult health care in Spain received the PIDJ award.

The study conducted at Vall d'Hebron shows that having a high level of neurofilament light chains translates, over the years, to a higher level of disability.

Vall d'Hebron és referent en el diagnòstic i abordatge multidisciplinari de l’esteatohepatitis no alcohòlica i liderem el nombre d’assajos clínics a l’Estat sobre NASH.

Researchers have generated a female and male pig model of ischemia/reperfusion renal injury and organ regeneration to study sex differences.

The two studies awarded has been the research for a the ciliary dyskinesia diagnosis led by the VHIR’s Growth and Development Group and the EPISCAN II, in which Dr. Miravitlles has participated.

Els estudis, dins el projecte BEACON, descriuen l’eficàcia d’un nou tractament amb immunoteràpia per al neuroblastoma i la utilitat de nous biomarcadors per predir el pronòstic i la resposta a la teràpia.

Per donar una segona vida als acumuladors de fred que s'usen als laboratoris clínics, després d’higienitzar-los estan disponibles per a totes les unitats assistencials per ser usats amb pacients.

HIV infected cells expressing the CD32 molecule are more resistant to the action of the natural killer cells of the immune system, which are key in the fight against viral infections.

The work was one of the first to identify skin lesions associated with SARS-CoV-2 infection in children at the beginning of the pandemic.

28 talented young people have presented their proposals for the metropolis' future after a 9-month immersion in its power structures under the guidance of Barcelona Global.

Aquest matí, pacients i professionals han escrit missatges amb raons per no fumar en dos plafons dissenyats per a l'ocasió i han obtingut obsequis a canvi.

The research aims to identify which patients with isolated radiological syndrome are more likely to develop the disease.

L’Hospital Universitari Vall d’Hebron acull en el Cemcat l’atenció al pacient amb esclerosi múltiple, convertint-se en un hospital capdavanter en el diagnòstic i tractament d’aquesta patologia.

Durant el mes de juny, organitzem tres activitats sobre assaigs clínics, genètica i imatges científiques.

El director del programa ECMO de Vall d’Hebron va participar en la darrera edició del congrés EuroELSO, que va celebrar-se a Londres aquest mes de maig.

The study showing how thrombocytopenia increases the risk of thrombosis in patients with antiphospholipid syndrome has been considered the best paper published in 2021.

Aquesta trobada es dirigeix a un públic de totes les edats amb un ampli ventall de formats: experiments, instal·lacions, jocs, tallers, demostracions, espectacles, debats, microxerrades, itineraris i visites guiades, entre d’altres.

The identification of genetic alterations is key to be able to administer targeted therapies to each patient.

EXIMIOUS is a project funded by the Horizon 2020 program that aims to study the exposome to understand its relationship with immune-mediated diseases.

Un total de 2.873 pacients van participar en els assaigs clínics que Vall d’Hebron va fer l’any 2021, un any en què es van posar en marxa 443 assaigs nous. 

EU-PEARL hopes to transform standard clinical trials into collaborative multi-compound research platforms focused on patients.

The head of the Medical Molecular Imaging group at VHIR received the recognition for the best poster presentation for a study on myocardial insulin resistance and cardiovascular risk.

For two days, 30 people between Hepatologia¡ unit researchers and industry experts have laid the foundations for this project.

VHIR collaborates with Nanbiosis through the FVPR service platform created within the Drug Delivery and Targeting Research Group (DTT).